For a patient with relapsed multiple myeloma after one to three prior lines who has rapidly progressive disease and cannot safely wait for CAR T-cell manufacturing, which approach does the speaker favor?
Proceeding with CAR T-cell therapy regardless, since its one-and-done nature outweighs the risks of waiting
An immediately available, off-the-shelf bispecific antibody approach, such as teclistamab alone or teclistamab-daratumumab, depending on prior exposure and refractoriness
Deciding mainly on chronological age, with bispecifics reserved for older patients and CAR T-cell therapy for younger patients